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Transferrin receptor 1 (TfR) plays a critical role in cellular iron import for most higher organisms. Cell surface TfR binds
to circulating iron-loaded transferrin (Fe-Tf) and transports it to acidic endosomes, where low pH promotes iron to
dissociate from transferrin (Tf) in a TfR-assisted process. The iron-free form of Tf (apo-Tf) remains bound to TfR and is
recycled to the cell surface, where the complex dissociates upon exposure to the slightly basic pH of the blood. Fe-Tf
competes for binding to TfR with HFE, the protein mutated in the iron-overload disease hereditary hemochromatosis.
We used a quantitative surface plasmon resonance assay to determine the binding affinities of an extensive set of site-
directed TfR mutants to HFE and Fe-Tf at pH 7.4 and to apo-Tf at pH 6.3. These results confirm the previous finding that
Fe-Tf and HFE compete for the receptor by binding to an overlapping site on the TfR helical domain. Spatially distant
mutations in the TfR protease-like domain affect binding of Fe-Tf, but not iron-loaded Tf C-lobe, apo-Tf, or HFE, and
mutations at the edge of the TfR helical domain affect binding of apo-Tf, but not Fe-Tf or HFE. The binding data
presented here reveal the binding footprints on TfR for Fe-Tf and apo-Tf. These data support a model in which the Tf C-
lobe contacts the TfR helical domain and the Tf N-lobe contacts the base of the TfR protease-like domain. The
differential effects of some TfR mutations on binding to Fe-Tf and apo-Tf suggest differences in the contact points
between TfR and the two forms of Tf that could be caused by pH-dependent conformational changes in Tf, TfR, or both.
From these data, we propose a structure-based model for the mechanism of TfR-assisted iron release from Fe-Tf.
Introduction
Transferrin receptor 1 (TfR) is a homodimeric type II
membrane protein that plays a critical role in the primary
iron acquisition mechanism for all iron-requiring cell types
in vertebrates (Enns 2002). TfR binds the serum iron-carrier
protein transferrin (Fe-Tf) and imports it to acidic endo-
somes, where iron is released and transported to the cytosol.
The complex between TfR and iron-free transferrin (apo-Tf)
is then recycled to the cell surface where apo-Tf dissociates
and returns to circulation (reviewed in Enns et al. 1996). TfR
also binds the hereditary hemochromatosis protein HFE
(Parkkila et al. 1997; Feder et al. 1998). HFE is a class I major
histocompatibility complex (MHC)-related protein that is
mutated in patients with hereditary hemochromatosis (Feder
et al. 1996), an iron-storage disease characterized by excessive
iron absorption leading to an accumulation of iron princi-
pally in the liver, heart, pancreas, parathyroid, and pituitary
gland, leading to tissue damage (Cullen et al. 1999).
The X-ray crystal structures of the human TfR ectodomain,
both alone (Lawrence et al. 1999) and in complex with HFE
(Bennett et al. 2000), have been reported. The homodimeric
TfR ectodomain contains three domains on each polypeptide
chain: a protease-like domain resembling amino- and
carboxypeptidases (residues 121–188 and 384–606), an apical
domain (residues 189–383), and a helical domain involved in
TfR homodimerization (residues 607–760). Intact TfR also
includes a glycosylated stalk region (residues 90–120), a
transmembrane domain (residues 62–89), and an N-terminal
cytoplasmic domain (residues 1–61) that includes a tyrosine-
based endosomal sorting sequence (YTRF) (Enns 2002). The
structure of a 2:1 HFE/TfR complex (two HFEs bound to a
homodimeric TfR) shows that each HFE interacts with helices
1 and 3 of the TfR helical domain (Bennett et al. 2000) (Figure
1A and 1B). The central portion of the interface includes a
hydrophobic core consisting of TfR residues Leu619, Val622,
and Tyr643 packed against hydrophobic residues from the a1
domain helix of HFE.
The structures of various transferrins (Tfs) and related
proteins such as lactoferrin have been studied extensively by
X-ray crystallography (Bailey et al. 1988; Anderson et al. 1989;
Gerstein et al. 1993; Zuccola 1993; Kurokawa et al. 1995, 1999;
Baker et al. 1998; Karthikeyan et al. 1999). Tf and its relatives
are single-chain molecules consisting of two similarly folded
lobes (the N- and C-lobes), each of which contains two
domains (NI and NII in the N-lobe; CI and CII in the C-lobe).
Diferric Tf (Fe-Tf) contains two iron atoms, each held in a
cleft between the domains of each lobe. Transition between
the ferric and iron-free states of Tf involves signiﬁcant
conformational changes (Grossmann et al. 1992, 1993).
Speciﬁcally, loss of iron results in a 548–638 rotation between
the two domains that comprise each lobe (Gerstein et al.
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1993). Additionally, the interface between the lobes repacks,
exposing previously buried residues and burying previously
exposed residues (Kurokawa et al. 1999). In vivo, these
conformational changes presumably take place while Tf is
bound to TfR, as the two proteins remain complexed
throughout endocytosis and recycling (Dautry-Varsat et al.
1983).
Free Fe-Tf releases iron at acidic pH, but binding to TfR
affects the iron release at both basic and acidic pH (Bali and
Aisen 1991, 1992; Bali et al. 1991). At pH 7.4, iron release
from Fe-Tf bound to TfR is slower than from free Fe-Tf. At
low pH, the opposite effect is observed, such that binding to
TfR signiﬁcantly increases the iron-release rate (Bali and
Aisen 1991, 1992; Bali et al. 1991; Sipe and Murphy 1991).
Attempts to determine the mechanism by which TfR mediates
these effects on the iron release rate have been hampered by
a lack of detailed knowledge of the binding footprints of Fe-
Tf and apo-Tf on TfR and by the unavailability of crystal
structures of Fe-Tf or apo-Tf bound to TfR.
Although the structural details of the interaction between
Tf and TfR remain unknown, early studies established that
two Tf molecules bind to each TfR homodimer (Enns and
Sussman 1981) by primarily interacting with what is now
structurally deﬁned as the TfR helical domain (Buchegger et
al. 1996). A subsequent mutagenesis study further localized
the binding site to include a conserved RGD sequence
(residues 646–648) within the TfR helical domain (Dubljevic
et al. 1999). The HFE/TfR co-crystal structure revealed that
HFE directly contacts TfR residues 646 and 648 (Bennett et al.
2000), which is consistent with biochemical inhibition studies
that suggested that HFE and Tf bind to the same or an
overlapping site on TfR (Lebro´n et al. 1999). As Fe-Tf is a
large protein (approximately 90A˚ 3 50A˚ 3 40 A˚, measured
using the structure of iron-bound ovo-Tf [Kurokawa et al.
1995]), the remainder of the Tf contact site on TfR could
include other TfR domains, the TfR interdomain cleft, or
both (Figure 1B), as previously suggested (Lawrence et al.
1999). A subsequent mutagenesis study sought to identify
other Tf-contacting residues on TfR (West et al. 2001). In that
study, residues identiﬁed from the HFE/TfR co-crystal
structure as involved in contacting HFE were mutated, and
their effects on binding to HFE and Fe-Tf were quantitatively
evaluated. These experiments identiﬁed several residues
within the TfR helical domain that are involved in binding
to each protein (deﬁned as a substitution producing a greater
than or equal to 5-fold reduction in binding afﬁnity) and
conﬁrmed that the Fe-Tf- and HFE-binding sites on TfR
overlap. However, the larger size of Tf relative to the HFE
ectodomain (679 amino acids in Tf compared with 374 for the
HFE/b2-microglobulin ectodomain) suggested that Fe-Tf
could contact residues outside of the TfR helical domain.
Also, the effects of the TfR substitutions on binding to apo-Tf
were not evaluated; thus, the question of whether Fe-Tf and
apo-Tf bind differently to TfR was not addressed.
We therefore sought to expand the library of TfR mutants
to more extensively map the Fe-Tf interface and to compare
the effects of TfR mutants for binding to Fe-Tf versus apo-Tf.
Here we report the afﬁnities of 30 mutants of human TfR for
binding to HFE and Fe-Tf at pH 7.5 and to apo-Tf at pH 6.3.
As expected, the most important residues for Tf binding are
located in the center of the TfR helical domain in the vicinity
of critical residues for HFE binding. However, we also
identiﬁed residues within the TfR protease-like domain that
make signiﬁcant contributions to binding of Fe-Tf, but not
apo-Tf, to TfR. Conversely, substitution of residues at the
edge of the TfR helical domain affects binding of apo-Tf, but
not Fe-Tf. This information, together with the identiﬁcation
of common Fe-Tf- and apo-Tf-contacting residues within the
helical domain, constrains the possible positions of Fe-Tf and
apo-Tf on TfR, allowing for construction of structural models
for the placement of the two forms of Tf on TfR. Our data
also suggest a structural mechanism to explain TfR’s role in
the pH-dependent modulation of iron release rates from Fe-
Tf.
Figure 1. TfR Structure
(A) Ribbon diagram of TfR homodimer
derived from the 3.2 A˚ structure of TfR
(Lawrence et al. 1999). The HFE-binding
site (deduced from an analysis using the
HFE/TfR co-crystal structure [Bennett et
al. 2000]) on the TfR helical domain
closest to the viewer is highlighted in
cyan.
(B) Space-ﬁlling representation of one
chain from the TfR homodimer, with the
HFE structural epitope residues high-
lighted as in (A). The location of the
interdomain cleft is indicated by an
orange asterisk.
(C–E) Summary of effects of TfR sub-
stitutions for binding HFE (C), Fe-Tf (D),
and apo-Tf (E). Color-coding of the TfR
sidechains designates the effects of the
substitutions on binding afﬁnities as
indicated.
Figures were made with Molscript (Krau-
lis 1991) or GRASP (Nicholls et al. 1993)
and rendered with Raster3D (Merritt and
Bacon 1997).
DOI: 10.1371/journal.pbio.0000051.g001
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Results
Design of TfR Mutants
Our choice of TfR residues to substitute was guided by the
crystal structures of TfR alone and bound to HFE (Lawrence
et al. 1999; Bennett et al. 2000) and by a previous binding
study involving ten TfR point mutants (West et al. 2001) (§
symbol in Table 1). Four substitutions at the HFE-binding site
on the TfR helical domain (L619A, R629A, Y643A, and
F650A) were found to signiﬁcantly reduce (greater than or
equal to 5-fold) the binding afﬁnity for both HFE and Fe-Tf at
pH 7.5, giving a ﬁrst-order map of the Fe-Tf-binding site on
TfR (West et al. 2001). In order to identify additional TfR
residues critical for Fe-Tf binding and to evaluate their
effects on apo-Tf binding, we extended our TfR mutant
library to include an additional 20 mutants. The new set of
mutations were chosen using three different strategies: (1) an
alanine scan involving solvent-exposed residues on helix 3 of
the helical domain (R651A, S654A, T658A, N662A, E664A)
(classiﬁed as H3 in Table 1); (2) substitution of residues in the
TfR interdomain cleft (see Figure 1B), suggested to be part of
the Fe-Tf-binding site (Lawrence et al. 1999), for the residues
of chicken TfR, which does not bind human Tf (Buchegger et
al. 1996) (P710R, K717Q) (classiﬁed as IDC in Table 1); (3)
mutation of large solvent-exposed hydrophobic residues,
which often provide much of the free energy of binding in
protein–protein interactions (Jones and Thornton 1996; Tsai
et al. 1997; Lo Conte et al. 1999), throughout the remaining
TfR surface area (Y123S, F187A, F396A, F521A, Y523S,
W528A, W702A, F760A) (classiﬁed as Hu in Table 1). A
second generation of mutants was subsequently made to
further deﬁne newly identiﬁed binding sites (W124A, D125K,
E606K, D610A) and to test the effect of combining sub-
stitutions (Y123S/G647A). Mutants involving TfR residues
known from the HFE/TfR crystal structure (Bennett et al.
2000) to contact HFE are denoted as part of the HFE
structural epitope in Table 1.
TfR mutants were expressed as N-terminally 6x-His-tagged
soluble ectodomains in baculovirus-infected cells, as pre-
viously described (Lebro´n et al. 1998; West et al. 2001). In a
previous TfR mutagenesis study, it was shown that mutants
that had a strong effect on binding were properly folded as
determined by comparison of their far-UV circular dichroism
spectra and gel ﬁltration proﬁles to that of wild-type TfR
(West et al. 2001). In this study, we note that all of the newly
made mutants retain wild-type or near wild-type binding
afﬁnities for at least one of the three TfR ligands tested (HFE,
Fe-Tf, or apo-Tf) (Table 1), conﬁrming their structural
integrity.
Affinity Measurements and Analyses
Each of the TfR mutants designed in the current screen,
plus the mutants from the previous study (West et al. 2001),
were tested in a surface plasmon resonance-based assay for
binding to either a soluble form of HFE at pH 7.5, Fe-Tf at pH
7.5, or apo-Tf at pH 6.3 (Table 1; Figure 2). For these
experiments, ﬁltered insect cell supernatants containing
secreted recombinant TfR mutants were injected over a
biosensor chip to which an anti-pentaHis antibody had been
immobilized. The antibody captures TfR by binding to its two
6x-His tags, thereby allowing oriented coupling of the
receptors to the biosensor chip. HFE, Fe-Tf, or apo-Tf was
then injected over the antibody/TfR-coupled sensor chip, and
binding data were ﬁt to a bivalent ligand model in which
equilibrium dissociation constants (KD1 and KD2) were
derived for binding to the ﬁrst and the second binding sites
on homodimeric TfR (see Table 1) (West et al. 2001).
Our previous mutagenesis study established that both the
HFE- and Fe-Tf-binding sites on TfR include residues within
helices 1 and 3 of the TfR helical domain (West et al. 2001)
(see Figure 1A and 1B). In the present study, we tested the
previously prepared TfR mutants for binding apo-Tf at pH
6.3 and re-evaluated their binding to HFE and Fe-Tf at pH
7.5. In agreement with the previous results, we found that two
Figure 2. Biosensor Analyses of Tf Binding
to Immobilized Wild-Type and Selected
Mutant TfR Molecules
Sensorgrams (black lines) of injected Fe-
Tf or apo-Tf binding to wild-type TfR
(top left) or the indicated TfR mutants
are shown with best-ﬁt binding curves
(red lines) derived from a bivalent ligand
model (see Materials and Methods)
superimposed. The sensorgrams demon-
strate that the binding responses are
concentration dependent, and the super-
imposed binding curves demonstrate the
close ﬁt of the binding model to the
experimental data. Concentrations of
injected proteins for each sensorgram
are given below as two numbers: the ﬁrst
is the highest injected concentration
(nM), and the second is the dilution
factor, either 2-fold (23) or 3-fold (33),
that relates successive injections. For
each TfR sample, there are two sets of
numbers, the ﬁrst being for Fe-Tf and
the second for apo-Tf. Wild-type (31, 23;
200, 23), Y123S (250, 23; 330, 33), W124A
(2,000, 33; 2,000, 23), D125K (2,000, 33;
1,000, 23), W641A (110, 33; 1,000, 33),
G647A (6,000, 33; 780, 33), R651A (5,000,
33; 1,000, 33), F760A (110, 33; 270, 33).
DOI: 10.1371/journal.pbio.0000051.g002
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 344
Mutagenesis of Transferrin Receptor
mutants, L619A and Y643A, showed no detectable HFE
binding and a signiﬁcant (greater than or equal to 5-fold)
decrease in Fe-Tf binding. These substitutions also signiﬁ-
cantly reduced apo-Tf binding at acidic pH. Two other
mutants, R629A and Q640A, were again found to signiﬁcantly
reduce HFE binding and to have a relatively minor effect on
Fe-Tf binding (R629A) or no signiﬁcant effect (Q640A). The
effects of these substitutions on apo-Tf binding correlated
with their effects on Fe-Tf binding. Likewise, the F650A
mutant, which shows a moderate reduction in binding afﬁnity
for both HFE and Fe-Tf, also shows a reduced afﬁnity for
binding apo-Tf. Only one of the previously analyzed mutants,
G647A, exhibited a major (greater than 100-fold) reduction in
Fe-Tf binding afﬁnity, and the present analysis reveals that it
has a similar effect on apo-Tf binding. Interestingly, one of
the previously analyzed mutants, W641A, which does not
signiﬁcantly affect HFE or Fe-Tf binding at pH 7.5, exerted a
signiﬁcant reduction in the binding afﬁnity for apo-Tf at pH
6.3 (see Table 1; Figure 1E; Figure 2), suggesting that it might
be possible to ﬁnd additional substitutions with differential
effects on binding of the two forms of Tf.
Our ﬁrst strategy for ﬁnding additional residues critical for
Tf binding involved substitution of solvent-exposed residues
C-terminal to the Tf-binding epitope residues Gly647 and
Phe650 on helix 3 of the TfR helical domain. Of the ﬁve new
TfR mutants constructed (R651A, S654A, T658A, N662A,
E664A), only one (R651A) affected Tf binding, resulting in a
greater than 2,800-fold reduction in binding of Fe-Tf and
apo-Tf. Having identiﬁed a ‘‘hot spot’’ for Tf binding
involving TfR helical domain residues Gly647 and Arg651,
we then searched for residues affecting Tf binding that were
distant from this site, which would allow approximate
positioning of the bi-lobed Tf structure on TfR. Two residues
within the cleft formed by portions of the three TfR domains
were changed to their chicken TfR counterparts to test the
prediction that Tf binds to the TfR interdomain cleft
(Lawrence et al. 1999). There were no signiﬁcant differences
in Tf binding afﬁnity for either the P710R or the K717Q
mutants, suggesting that at least this region of the interdo-
main cleft is not critical for binding to either form of Tf.
Consistent with this interpretation, we found a second
binding site at the base of the TfR protease-like domain that
is distant from the interdomain cleft (approximately 46 A˚).
The Y123S mutant, which was constructed as part of a screen
to test the effects of changing large solvent-exposed hydro-
phobic residues, shows a signiﬁcantly reduced afﬁnity for Fe-
Tf, but not to apo-Tf or HFE. To conﬁrm that Tyr123 forms
part of the Fe-Tf-binding site, three additional mutants were
constructed: the double mutant Y123S/G647A and the two
single mutants W124A and D125K. The double mutant
showed an increased effect on Fe-Tf binding compared to
the G647A alone, consistent with the involvement of Tyr123
in Fe-Tf binding. In addition, the W124A and D125K single
mutants, which change residues adjacent to Tyr123, also
reduced TfR’s afﬁnity for Fe-Tf, but not apo-Tf. Thus, the
base of the protease-like domain in the vicinity of Tyr123 is
involved in differential binding to the iron-loaded form of Tf,
but not apo-Tf. None of the other substitutions constructed
in the screen of solvent-exposed hydrophobic residues
signiﬁcantly affected binding to either form of Tf or to HFE.
As Tf is a bi-lobed structure, it should be possible to
evaluate the binding of isolated lobes to wild-type and mutant
TfRs to gain information regarding the positions of the two
Tf lobes on TfR. Isolated iron-loaded Tf C-lobe (Fe-C-lobe)
binds to TfR with an afﬁnity of approximately 650 nM (Zak et
al. 1994; Zak and Aisen 2002). Assuming independent binding
of the two Tf lobes without effects of cooperativity, the
afﬁnity increase to a KD of approximately 1 nM for intact Fe-
Tf binding to TfR suggests the KD for binding isolated N-lobe
would be approximately 1.5 mM. This afﬁnity is too weak to
be detected by most binding assays. Consistent with this
assumption, isolated Tf N-lobe neither binds detectably to
TfR nor donates iron to TfR-expressing cells (Zak et al. 1994;
Mason et al. 1997). We therefore tested puriﬁed Fe-C-lobe
(Zak and Aisen 2002) for binding to wild-type TfR and
selected TfR mutants.
Fe-C-lobe was injected over wild-type TfR and TfR mutants
(Y123S, D125K, R651A, F760A) in a biosensor binding assay as
described for Fe-Tf above. Binding data were analyzed using
an equilibrium-based approach because the rapid kinetics of
the Fe-C-lobe interaction with wild-type TfR do not allow
accurate derivation of kinetic rate constants (Figure 3). No
signiﬁcant changes in afﬁnity were observed for Fe-C-lobe
binding to two mutants in the TfR protease-like domain
(Y123S, D125K), but a mutation in the central portion of the
Fe-Tf functional epitope on TfR, R651A, eliminated detect-
able binding (Figure 3). In addition, binding of Fe-C-lobe was
not signiﬁcantly affected by the F760A mutation in the TfR
helical domain, which reduces the afﬁnity of apo-Tf, but not
Fe-Tf (see Figure 2; Table 1). These results suggest that Tf C-
lobe contacts the TfR helical domain, but not the protease-
like domain.
Figure 3. Biosensor Analyses of Fe-C-Lobe Binding to Immobilized Wild-
Type and Selected Mutant TfR Molecules
Plots of the equilibrium binding response, normalized to the Rmax
value (the ligand immobilization value) derived from ﬁtting, versus
concentration of injected Fe-C-lobe, are shown for the indicated TfR
mutants along with the wild-type TfR control that was present in an
adjacent ﬂow cell on the same biosensor chip. Best-ﬁt binding curves
derived from a bivalent ligand model are shown as solid lines
connecting the datapoints (squares for wild-type TfR and triangles
for TfR mutants). The R651A mutant exhibited no binding and was
not ﬁt. A summary of derived binding constants is shown in the lower
right panel. The KDs for wild-type TfR are averages derived from
three independent measurements, and the number after the plus/
minus sign represents the standard deviation.
DOI: 10.1371/journal.pbio.0000051.g003
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Discussion
Despite many years of investigation of the Tf/TfR pathway
for iron uptake, molecular details about the interaction
between TfR and Tf have been limited largely due to a lack of
structural information for a Tf/TfR complex. In the absence
of a three-dimensional structure, site-directed mutagenesis
can be used to map out a protein–protein interaction. To
narrow down a subset of residues for mutageneis from the
639 residues in a soluble TfR monomer, we used the crystal
structures of TfR alone (Lawrence et al. 1999) and TfR bound
to HFE (Bennett et al. 2000) to locate solvent-exposed
residues in the vicinity of the HFE-binding site, which was
suggested from competition studies to overlap with the Tf-
binding site on TfR (Lebro´n et al. 1999). We identiﬁed
residues within the TfR helical domain whose substitution
affected binding of both HFE and Fe-Tf at pH 7.5 in a
previous mutagenesis study involving ten human TfR mutants
(West et al. 2001). These results established that HFE and Fe-
Tf bind to the same or an overlapping site on TfR. In the
present study, we have expanded the library of TfR mutants
to more precisely map the Tf-binding site on TfR and
compared binding of Fe-Tf and apo-Tf to TfR. From a survey
of 29 point mutants of human TfR, we identiﬁed 11 residues,
which, when substituted, reduce the afﬁnity of TfR for either
human Fe-Tf, apo-Tf, or both (see Table 1). Six of the 11
residues are completely conserved in different species of TfR
and in a more recently identiﬁed Tf-binding receptor, TfR2,
which shares 45% sequence identity with TfR (Kawabata et al.
1999). Most notably, four of the residues exerting the largest
effects on Fe-Tf binding, apo-Tf binding, or both (Leu619,
Trp641, Gly647, and Arg651) are completely conserved across
all currently known TfR and TfR2 sequences (see Table 1).
Others, such as the tyrosines at positions 123 and 643, are
either conserved or conservatively substituted for phenyl-
alanine in some TfR species. By contrast, of the 18 positions
at which substitutions did not signiﬁcantly affect Tf binding,
16 are not conserved, and two (Phe187 and Glu664) are
conservatively substituted (see Table 1). These results suggest
that our conclusions about the mode of binding between
human Tf and human TfR can be generalized to include Tf/
TfR complexes from other species and the interaction
between TfR2 and Tf.
From a quantitative analysis of the afﬁnities of the
different TfR mutants for Fe-Tf and apo-Tf, we can classify
the residues we mutated using the criteria of Wells and
colleagues (Cunningham and Wells 1993), which categorize
the structural and functional epitope residues in a protein–
protein interaction. The functional epitope is deﬁned as
residues exerting a major effect on the binding afﬁnity (a
G value, 2 kcal/mol after substitution of a single residue,
corresponding to an afﬁnity reduction of at least 30-fold at
room temperature). The structural epitope on a protein is all
residues at the contact interface with the binding partner,
which can be deduced from a co-crystal structure (Cunning-
ham and Wells 1993). Substitution of some, but not all, of the
residues at the structural epitope of a protein–protein
interface will result in afﬁnity changes (Cunningham and
Wells 1993). This is illustrated in our study by comparing the
crystallographically-deﬁned structural epitope on TfR for
binding HFE (Bennett et al. 2000) (see Figure 1A and 1B;
Table 1; Figure S1) with the results of mutagenic mapping of
residues affecting HFE binding (see Figure 1C). In the absence
of a Tf/TfR co-crystal structure, we can use our mutagenesis
results to predict the functional and structural epitope
residues (afﬁnity reductions of greater than or equal to 30-
fold or between 5- and 30-fold, respectively) on TfR for
binding to Fe-Tf and apo-Tf. From the comparison of wild-
type and mutant TfR binding afﬁnities, Arg651 was identiﬁed
as a functional epitope residue for binding both Fe-Tf at pH
7.5 and binding apo-Tf at pH 6.3, as substitution of this single
residue to alanine greatly reduces binding to either form of
Tf (see Table 1). In combination with the previously studied
G647A mutant (Dubljevic et al. 1999; West et al. 2001), which
reduces afﬁnity for both Fe-Tf and apo-Tf by over 100-fold,
these residues deﬁne a functional epitope for Fe-Tf and apo-
Tf binding located in the bottom central portion of the TfR
helical domain (see Figure 1D and 1E). Two other nearby
residues, Leu619 and Trp641, can be considered part of the
functional epitope for binding apo-Tf. The HFE/TfR crystal
structure shows that these residues are at the contact
interface with HFE (see Figure 1A and 1B) (Bennett et al.
2000), but with the exception of Leu619, their substitutions
do not signiﬁcantly affect HFE binding (see Table 1). Instead,
the functional epitope for HFE binding is shifted slightly
upwards on the TfR helical domain from the Fe-Tf functional
epitope to include residues Leu619 and Tyr643 (see Figure
1C). Thus, although most of the functional epitope residues
for binding of HFE and Tf are physically separated, they are
close enough that binding of either HFE or Fe-Tf to TfR
would sterically preclude binding of the other species (see
Figure 1C and 1D). In addition, some substitutions in TfR
signiﬁcantly lower the afﬁnity for both HFE and Tf (L619A,
R629A, Y643A, and F650A) (see Table 1).
Since Tf is a larger molecule than HFE, we reasoned that Tf
could also interact with residues not contained in the HFE
binding footprint on TfR. We therefore tested substitutions
of residues outside of the TfR helical domain for their effects
on binding to Tf. To narrow down the search, we chose to
substitute solvent-exposed hydrophobic residues, which are
often found in protein–protein interfaces (Jones and Thorn-
ton 1996; Lo Conte et al. 1999). We also restricted the search
to residues within approximately 90 A˚ (the longest dimension
of Fe-Tf) of the Fe-Tf functional-binding epitope for
substitution. Using this strategy, we identiﬁed a region at
the base of the protease-like domain involving residues
Tyr123, Trp124, and Asp125, where substitutions showed
signiﬁcant effects on binding to Fe-Tf at pH 7.5, but not to
HFE at pH 7.5 or to apo-Tf at pH 6.3 (see Figure 1D and 1E;
Table 1). Having deﬁned two predicted Fe-Tf contact areas
on TfR that are separated by approximately 33 A˚ (measured
between TfR residues Arg651 and Tyr123) constrains the ways
in which Tf can interact with TfR. In particular, computer
modeling suggests that a single Tf lobe cannot make
productive contacts with both regions of TfR (A. M.
Giannetti, unpublished data); thus both lobes of Fe-Tf are
likely to be involved in the interface with TfR. Previous
studies of the binding of isolated Fe-N- and Fe-C-lobes of Tf
suggested that the majority of the binding energy in the Tf/
TfR interaction comes from the C-lobe (Zak et al. 1994; Zak
and Aisen 2002). It has also been observed that mixing
puriﬁed N- and C-lobes results in a signiﬁcant enhancement
of TfR binding over that of C-lobe alone (Mason et al. 1997;
Zak and Aisen 2002). These observations are consistent with a
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Tf orientation on TfR in which the C-lobe contacts the Tf
functional epitope on the TfR helical domain and the N-lobe
contacts the Tyr123 area at the base of the TfR protease-like
domain (Figure 4). In this model, allosteric effects need not be
invoked to explain the increased afﬁnity of the N-lobe/C-lobe
mixture over C-lobe alone (Zak and Aisen 2002). Instead, the
observed increase in afﬁnity is predicted to arise from direct
contacts between the N-lobe and TfR. To test the predicted
orientation of Tf on TfR (Figure 4), we compared the
afﬁnities of isolated Fe-C-lobe (Zak and Aisen 2002) to wild-
type TfR and to TfR mutants with substitutions in the helical
domain (R651A, F760A) and the protease-like domain (Y123S,
D125K) (see Figure 3). As predicted, substitutions in the
protease-like domain do not affect binding of Fe-C-lobe,
whereas a functional epitope substitution (R651A) in the TfR
helical domain eliminates detectable binding of Fe-C-lobe to
TfR.
Our binding data also allow us to assess potential differ-
ences in the binding of Fe-Tf versus apo-Tf to TfR. Two prior
observations are consistent with differences in the binding
footprints of Fe-Tf and apo-Tf on TfR. First, Fe-Tf undergoes
a large conformational change upon acidiﬁcation and release
of iron, as deduced by comparison of crystal structures of
ferric and iron-free forms of Tf and Tf-related molecules
such as the lactoferrins (Bailey et al. 1988; Anderson et al.
1989; Gerstein et al. 1993; Zuccola 1993; Kurokawa et al. 1995,
1999; Baker et al. 1998; Karthikeyan et al. 1999) (see Figure 4).
Second, TfR has been suggested to undergo a pH-dependent
conformational change resulting in aggregation at pH ,6 in
the absence of Tf (Turkewitz et al. 1988). Our ﬁnding of
differential effects of TfR substitutions for binding Fe-Tf at
pH 7.5 versus apo-Tf at pH 6.3 is consistent with conforma-
tional changes in Tf,TfR, or both at acidic pH. We ﬁnd one
TfR region that affects binding of Fe-Tf, but not apo-Tf (the
region near Tyr123 involving TfR residues 123–125 at the
base of the protease-like domain), and another region that
affects binding of apo-Tf, but not Fe-Tf or Fe-C-lobe (the
region deﬁned by Trp641 and Phe760, two spatially proximal
residues [10.2 A˚ apart] at the edge of the TfR helical domain)
(see Figure 1E and 1F). The apo-Tf-speciﬁc binding site may
be important for TfR’s ability to signiﬁcantly accelerate iron
release from receptor-bound Fe-Tf (Bali and Aisen 1991).
Taking all of our data into account, we propose the following
structure-based mechanism to explain TfR-assisted iron
release from Fe-Tf (see Figure 4; Video S1).
First, Fe-Tf binds to TfR at pH 7.5, with the C-lobe making
critical contacts to the TfR region deﬁned by Arg651 in the
helical domain and the N-lobe making additional favorable
contacts with the second Tf-binding site deﬁned by Tyr123,
Trp124, and Asp125. The interaction of the complementary
surfaces on each protein presumably limits Fe-Tf’s freedom
to sample more open states, thereby favoring the closed iron-
bound state and lowering the iron release rate from both Tf
lobes. This is consistent with the experimental evidence
(Navati et al. 2003) suggesting that iron release is reduced by
an order of magnitude under conditions favoring a closed Tf
conformation relative to conditions favoring an open
conformation.
Second, as the pH is lowered, protonation of key residues
in Fe-Tf allows it to sample open conformations that
facilitate iron release (Navati et al. 2003). A conformational
change in Tf, TfR, or both allows additional Tf interactions
between Tf and the hydrophobic binding surface deﬁned by
TfR residues Trp641 and Phe760. These new interactions
stabilize Tf in an open conformation exposing the iron-
binding site and thereby enhancing the rate of iron release.
The extensive mutagenic mapping of ligand binding to TfR
reported here has revealed residues responsible for func-
tional binding to HFE, Fe-Tf, and apo-Tf. These data conﬁrm
that HFE and Tf bind to a physically and functionally
overlapping site on the TfR helical domain, although the
most important receptor residues for binding are different
for the two proteins. Thus, HFE and Fe-Tf must compete with
each other for binding to cell surface TfR, which may have
functional signiﬁcance in HFE’s role in maintaining iron
homeostasis (Townsend and Drakesmith 2002). Additionally,
we have found that Fe-Tf makes speciﬁc contacts not only to
the TfR helical domain through its C-lobe, but also to the TfR
protease-like domain, which implies that there are speciﬁc N-
lobe/TfR contacts contributing to Tf binding. Finally, our
demonstration that Fe-Tf and apo-Tf have different binding
footprints on the surface of TfR provides insight into the
mechanism by which TfR binding differentially affects iron
release rates from Fe-Tf at acidic and basic pH.
Figure 4. Model for the Binding of Fe-Tf and
Apo-Tf to TfR
The ﬁgures representing each molecule are
drawn to scale as an outline around the
known structures of TfR (Lawrence et al.
1999), Fe-ovo-Tf (Kurokawa et al. 1995), and
apo-ovo-Tf (Kurokawa et al. 1999). Mem-
brane-bound TfR includes a stalk region that
places the TfR ectodomain about 30 A˚ above
the cell surface (Fuchs et al. 1998), which
would allow the Tf molecule to extend below
the plane of the TfR ectodomain. At basic
pH, Fe-Tf (orange, with the iron atom
positions shown as black dots) and TfR
(blue) associate to make a complex contain-
ing one TfR homodimer and two Fe-Tf
molecules, one bound to each polypeptide
chain of the TfR homodimer. Fe-Tf makes energetically favorable contacts at basic pH to residues identiﬁed by mutagenesis in the TfR helical
domain (red) and the protease-like domain (green). Acidiﬁcation results in iron release and large conformational changes in the Tf structure as
it becomes apo-Tf (gray). Apo-Tf does not make energetically favorable contacts with the protease-like domain, but retains binding to the helical
domain-binding site (red) and makes new contacts to the helical domain (yellow), thereby stabilizing the complex. Upon return to basic pH, the
apo-Tf molecules dissociate from TfR. This is also illustrated in Video S1.
DOI: 10.1371/journal.pbio.0000051.g004
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Materials and Methods
Preparation of TfR ligands. A soluble form of human HFE
(residues 1–275 of the mature protein noncovalently associated with
the light chain b2-microglobulin) was expressed and puriﬁed as
previously described (Lebro´n et al. 1998). Human Fe-Tf was prepared
from apo-Tf (Sigma, St. Louis, Missouri, United States) by incubation
with bicarbonate and excess ferric ammonium sulfate. Free iron was
removed by dialysis, and the protein was further puriﬁed by gel-
ﬁltration chromatography. Iron saturation was 100% as determined
spectrophotometrically (A465/A280, ;0.05) (He and Mason 2002).
Puriﬁed recombinant Fe-C-lobe was cleaved from a full-length Fe-
Tf in which the loop that connects the N- and C-lobes was replaced
with a Factor Xa site (Zak and Aisen 2002). Concanavalin A
chromatography was used to separate the glycosylated C-lobe from
unglycosylated N-lobe (Zak and Aisen 2002). Protein concentrations
were determined from the A280- value using extinction coefﬁcients of
52,200 M1 cm1 (Fe-C-lobe) (O. Zak, personal communication),
83,360 M1 cm1 (Tf), and 96,570 M1 cm1 (HFE/b2-microglobulin)
(Lebro´n et al. 1998).
Production of wild-type TfR and TfR mutants. Soluble human TfR
and TfR mutants were expressed in a lytic baculovirus/insect cell
expression system as previously described (Lebro´n et al. 1998).
Mutations were introduced through PCR mutagenesis (Quickchange,
Strategene, La Jolla, California, United States) into a baculovirus
expression vector (pACGP67A; Pharmingen, San Diego, California,
United States) containing a hydrophobic leader sequence, 6x-His tag,
Factor Xa site, and residues 121–760 of human TfR. All mutations
were conﬁrmed by DNA sequencing of the protein-coding region of
the vector. The Y123S mutation was further conﬁrmed by N-terminal
sequencing of the puriﬁed mutant protein, yielding the sequence
ADPHHHHHHSSGIEGRGEFRLSWDD (the serine substitution for
tyrosine is underlined), corresponding to residual leader sequence
residues (A), vector-encoded sequence (DP), the 6x-His tag, spacer
residues (SSG), a Factor Xa site (IEGR), a spacer segment (GEF), and
residues 121–126 of the mutant TfR (RLSWDD). The double mutant
Y123S/G647A was constructed by introducing the Y123S substitution
into the G647A–TfR expression construct, after which the protein-
coding region of the expression plasmid was again sequenced.
Recombinant viruses were generated by cotransfection of a transfer
vector with linearized viral DNA (Baculogold, Pharmingen). Super-
natants of baculovirus-infected High 5 cells were used as the source of
wild-type TfR and TfR mutants for surface plasmon resonance-based
afﬁnity measurements.
Afﬁnity measurements. We used a BIACORE 2000 biosensor
system (Pharmacia, LKB Biotechnology, Uppsalla, Sweden) to assay
the interaction between TfR and HFE, Fe-Tf, and apo-Tf as described
(West et al. 2001). Binding of injected proteins (the analytes were
HFE, Fe-Tf, or apo-Tf) to a protein immobilized on the sensor chip
(the ligand was TfR) results in changes in surface plasmon resonance
that are read out in real time as resonance units (RUs) (Fa¨gerstam et
al. 1992; Malmqvist 1993).
For each experiment, the four ﬂow cells of a CM5 biosensor chip
(Pharmacia) were prepared by covalently attaching an anti-His-tag
antibody (anti-PentaHis; Qiagen, Valencia, California, United States)
to a coupling density of 2,000–4,000 RUs through standard amine
coupling chemistry (BIACORE manual). Insect cell supernatants (50–
300 ll) containing secreted 6x-His-tagged wild-type or mutant TfR
were passed through a 0.2 lm ﬁlter and injected over one of the four
ﬂow cells of a biosensor chip at a ﬂow rate of 30 ll/min, resulting in
stable binding of TfR to density of 200–400 RUs. In a typical
experiment, a small amount of TfR immediately dissociates from the
anti-His antibody, but most TfR protein (.85%) remains bound
during the course of the injection of the TfR ligands, resulting in a
negligible baseline drift. On each biosensor chip, one ﬂow cell
containing only the immobilized antibody was used as the reference
cell, one cell containing wild-type TfR served as an internal control
for binding of the three TfR binding partners, and TfR mutants were
coupled to the other two ﬂow cells. HFE or Fe-Tf was injected over
the ﬂow cells at 50 ll/min or 70 ll /min, respectively, at 258 C in 50
mM PIPES (pH 7.5), 150 mM NaCl, and 0.005% surfactant P20 (v/v).
All analyte injections were made as serial 2- or 3-fold dilutions. The
HFE concentration series ranged from 30 nM to 10 lM, and the Fe-Tf
and apo-Tf injections typically spanned from 1 nM to 200 nM, except
for experiments involving low-afﬁnity mutants requiring higher
concentrations to properly derive afﬁnities (see legend to Figure 2).
In test experiments, the sensorgrams from duplicate injections could
be overlaid to within the experimental noise; thus, single injections
were done for each concentration of injected protein in a binding
experiment. Between successive injections of analytes, the chips were
regenerated to preinjection response levels by either ﬂowing with
running buffer until baseline was achieved (in the case of HFE) or by
a 12-second injection of the injection buffer containing 0.5 M MgCl2
(in the case of Fe-Tf). This treatment did not cause dissociation of
TfR from the anti-His-tag antibody. Apo-Tf was injected in 50 mM
PIPES (pH 6.3), 150 mM NaCl, 0.005% surfactant P20 (v/v), including
50 lM desferrioxamine as an iron chelator, and chip regeneration
was achieved with an injection of the same buffer at pH 7.5.
Raw sensorgram data were preprocessed using the Scrubber
software package (BioLogic Software, Campbell, Australia; www.bio-
logic.com.au). The response from the reference ﬂow cell was
subtracted from the experimental ﬂow cells to eliminate bulk
refractive index changes. The response from the average of at least
three buffer-only injections was then subtracted to correct for
potential systematic instrument artifacts. Kinetic constants were
obtained by simultaneous ﬁtting of the association and dissociation
phases of all curves in the working set using the program Clamp99
(Morton and Myszka 1998). The data were ﬁt to a bivalent ligand
model, which describes the two sequential binding events for either
Tf or HFE binding to homodimeric TfR. A simple 1:1 binding model
did not account for the observed data as judged from large residuals
in the ﬁts (data not shown). Equilibrium dissociation constants (KDs)
were calculated from the ratio of the dissociation and association rate
constants, koff (s
1) and kon (M
1s1), respectively, yielding KDs for the
ﬁrst and second binding events (KD1 and KD2) in the following
reaction mechanism:
Aþ TfR $ A:TfR ðrate constants: kon;1 and koff;1Þ
KD1 ¼ koff;1=kon;1
Aþ A: TfR $ A2 :TfR ðrate constants: kon;2 and koff;2Þ
KD2 ¼ koff;2=kon;2
where A is either HFE, Fe-Tf, or apo-Tf. For independent binding
sites, the apparent stepwise equilibrium dissociation constants (KD1
and KD2) are related to the intrinsic binding constants for the ﬁrst
and second binding events to TfR (KD,intrinsic and KD,intrinsic), as
follows:
KD1;intrinsic ¼ KD1=2
KD2;intrinsic ¼ 2KD2
Hence, if the binding of a TfR ligand is independent of whether a
ligand is bound on the other face of the TfR homodimer, KD2¼ 4KD1.
For each mutant, the relative effect on HFE, Fe-Tf, or apo-Tf
binding was calculated as a ratio between the mutant KD and the
average of 22 independent determinations of the wild-type KD (see
Table 1) and as a ratio between the mutant KD and the wild-type KD
derived from wild-type protein coupled to a ﬂow cell on the same
sensor chip as the mutant (data not shown). No signiﬁcant differences
were found for the two methods of calculating the ratios. All mutants
were evaluated for HFE and Fe-Tf binding in at least two
independent experiments. For apo-Tf binding, those mutants that
showed a signiﬁcant difference in binding compared to wild-type TfR
were reevaluated in a separate, independent experiment. No
signiﬁcant differences in KDs were observed in independent
determinations of mutant afﬁnities. When accurate afﬁnities could
not be derived in a duplicate experiment due to problems with
baseline drift, visual inspection of the sensorgrams demonstrated that
each mutant exerted the same relative effects compared with wild-
type TfR in independent binding experiments. Table 1 presents
afﬁnities derived from one binding experiment per mutant/ligand
pair. The reproducibility of the binding experiments can be assessed
by the standard deviation of the wild-type TfR afﬁnity for each of the
ligands (derived from 22 independent binding experiments) and from
the fact that the afﬁnities of many of the mutants are not signiﬁcantly
changed compared to wild-type TfR.
For binding interactions involving the Fe-C-lobe, which reach
equilibrium quickly, we derived KDs using an equilibrium-based
approach. In these experiments, KDs were derived by non-linear
regression analysis of plots of Req (the equilibrium binding response)
versus the log of the analyte concentration. The data were ﬁt to a
binding model assuming a bivalent ligand in BIAevaluation 3.0
(BIACORE). We were unable to detect signiﬁcant amounts of binding
between apo-C-lobe and wild-type TfR at pH 6.3, presumably due to
an intrinsically weak binding afﬁnity.
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Supporting Information
Figure S1. G for Mutant TfR Binding to HFE, Fe-Tf, and Apo-Tf
Histogram of G values for the change relative to wild-type TfR in
TfR mutant afﬁnities for HFE (blue), Fe-Tf (pink), and apo-Tf (gray).
G values (the difference in binding energy for a mutant TfR
compared to wild-type TfR) were calculated using the KD1 values
from Table 1 as G¼RTln(KD1,mut/KD1,wild-type), where R is the gas
constant (1.99 3 103 kcal mol1 K1), and T is the temperature in
degrees Kelvin (298 K). The dashed green line represents the cutoff
for TfR mutants with a greater than or equal to 5-fold afﬁnity
reduction in ligand binding, and the dashed red line indicates a
greater than or equal to 30-fold afﬁnity reduction. An orange star
indicates non-binding mutants and mutants with a greater than 160-
fold afﬁnity reduction whose G values exceed the y-axis limit of
the histogram (L619A and Y643A, 4 kcal/mol; G647A¼ 3.2 kcal/mol;
and R651A, 4.6 kcal/mol).
View online at DOI: 10.1371/journal.pbio.0000051.sg001 (1.86 MB
TIFF).
Video S1. Model of TfR-Assisted Iron Release from Fe-Tf
View online at DOI: 10.1371/journal.pbio.0000051.sv001 (12 MB
MOV).
Accession Numbers
The SwissProt accessions numbers for the proteins discussed in
this paper are b2-microglobulin (P01884), Fe-Tf (P02787), HFE
(Q30201), TfR canine (Q9GLD3), TfR chicken (Q90997), TfR feline
(Q9MYZ3), TfR hamster (Q07891), TfR human (P02786), TfR mouse
(Q62351), TfR rat (Q99376), TfR2 human (Q9UP52), and TfR2 mouse
(Q62351).
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